INS and metabolic dysfunction-associated steatotic liver disease: Pio has beneficial effects on insulin sensitivity and nonalcoholic fatty liver disease (NAFLD) in experimental animal models [3–7], and this drug is approved for treatment of insulin-resistant diabetes in humans [8].